From “Safe Harbor” To Spotlight: Pharmacogenomics Comes Of Age At FDA
This article was originally published in RPM Report
Executive Summary
An FDA/industry workshop on pharmacogenomics and biomarkers highlighted how far the regulatory system for PKG has evolved. Where industry was afraid to share data with FDA, the conversation is now about how to get the agency the resources it needs to review the data effectively.
You may also be interested in...
FDA Seeks Regulatory Science ‘Bridge’ To Find Pharmacogenomics Biomarkers
Incoming Acting Commissioner Stephen Ostroff co-authors paper urging standardization of bioinformatics to speed development of safety and efficacy markers.
Biomarkers In Labeling Lack Clinical Utility Evidence
FDA-approved labels for more than 100 drugs feature pharmacogenomic biomarker data, but only one-sixth of those biomarkers are supported by data showing a clear association with health benefits, a JAMA study found. Researchers recommend stricter standards and a standardized pharmacogenomics section of labeling.
COPD Patient-Reported Outcome Questionnaire Is Early Example of FDA Drug Development Tool “Approval” Process
FDA finalizes the "qualification process for drug development tools." The topic won't get as much attention as Breakthrough Therapy or Accelerated Approval, but the head of the drug center thinks this is a very big deal. A COPD outcomes assessment is an early example of the process in action.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: